CAMBRIDGE, Mass. & BOULDER, Colo.–(BUSINESS WIRE)–Archemix Corp. and SomaLogic, Inc. announced today an expansion of their alliance focused on the use and development of aptamers for therapeutic, diagnostic, and other applications.
Trending at Lumira Ventures
Alexza Pharmaceuticals to Announce Second Quarter 2007 Financial Results on August 13, 2007
Learn More-External Link
Replidyne Announces Second Quarter 2007 Earnings
Learn More-External Link
Archemix Files for IPO
Learn More-External Link
Pharmasset and Roche Initiate Studies to Advance R7128 for HCV
Learn More-External Link
Nasrat Hakim Joins Alexza Pharmaceuticals as Vice President, Quality
Learn More-External Link
Depomed Announces Results of Phase 3 Clinical Trial for Gabapentin GR(TM) In Postherpetic Neuralgia
Learn More-External Link
U-Systems, Inc. Raises $16.5M in Additional Venture Funding
Learn More-External Link
Morphotek CEO Named Ernst & Young Entrepreneur Of The Year® 2007 Award Winner
Learn More-External Link
MAKO Surgical Corp. CEO is named Ernst & Young Entrepreneur Of The Year
FORT LAUDERDALE, Fla. – MAKO Surgical Corp. announced today that its President & CEO Maurice R. Ferré, M.D., has received the Ernst & Young Entrepreneur of the Year 2007 award for emerging companies in Florida. The Ernst & Young Entrepreneur …
Replidyne Announces Positive Phase I Results for Topical Antibiotic REP8839
Learn More-External Link
Healthcare Acquisition Corp. and Pharmathene receive stockholder approval for their merger
DES MOINES, IA and ANNAPOLIS, MD, August 3, 2007 – Healthcare Acquisition Corp. (AMEX: HAQ), a publicly-traded special purpose acquisition company, and PharmAthene, Inc., a biodefense company developing and commercializing medical countermeasures againstbiological and chemical threats, today announced that the …
Alexza Pharmaceuticals Expands Staccato(R) Migraine Product Portfolio
Learn More-External Link
Archemix and Merck KGaA Sign Strategic Alliance
Cambridge, MA – June 11, 2007 – Archemix Corp. and Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that they have formed a multi-year strategic alliance to discover, develop and commercialize first-in-class aptamer therapeutics with a primary focus …
Archemix and Takeda to Enter into Collaboration for Discovery and Development …
Cambridge, MA and Osaka, Japan — June 11, 2007 — Archemix Corp. (“Archemix”) and Takeda Pharmaceutical Company Limited (“Takeda “) announced today that both parties have signed a multi-year, three target agreement that focuses on the discovery, development and commercialization of first-in-class aptamer-based therapeutics. Under …